Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Adv 2019 Jul 09;3(13):1926-1929
Date
06/28/2019Pubmed ID
31243002Pubmed Central ID
PMC6616259DOI
10.1182/bloodadvances.2018025726Scopus ID
2-s2.0-85068800678 (requires institutional sign-in at Scopus site) 46 CitationsAbstract
Children treated with blinatumomab for B-ALL with MRD had few side effects and proceeded to hematopoietic cell transplant without delay. Blinatumomab given prior to transplant reduces MRD and results in favorable leukemia-free survival, toxicity, and overall survival.
Author List
Keating AK, Gossai N, Phillips CL, Maloney K, Campbell K, Doan A, Bhojwani D, Burke MJ, Verneris MRAuthor
Michael James Burke MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAntibodies, Bispecific
Antineoplastic Agents
Child
Child, Preschool
Female
Humans
Incidence
Infant
Infant, Newborn
Male
Neoplasm, Residual
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Stem Cell Transplantation
Treatment Outcome
Young Adult